Clinical trials: COPD Exacerbation
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease Markers and Prognosis
The study aim is to verify the association between the changes in markers of disease and patient´s prognosis in chronic obstructive pulmonary disease.
- Trial name
- NCT00605540
- Where
- Brazil
- Volunteers
- 133 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
COPD Exacerbation
Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD
The primary objective of the study is to determine the percentage of patients with "therapeutic success" at the end of the cycle of antibiotic therapy (10 days), in the two treatment groups (levofloxacin and prulifloxacin).
- Trial name
- FLOR (NCT01710488)
- Testing
- Levofloxacin 1 tablet 500 mg once a day, Prulifloxacin 1 tablet 600 mg once a day
- Where
- 25 sites in Italy
- Volunteers
- 258 people
- Sponsor
- Fadoi Foundation, Italy
Pulmonary Disease, Chronic Obstructive
Digihaler in Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-center 3-month study to determine the variation in ProAir Digihaler metrics [peak inspiratory flow (PIF), inhalation volume, number of inhalation events] amongst COPD patients in the ambulatory setting.
- Trial name
- NCT05241288
- Testing
- Albuterol eMDPI DS
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of North Carolina, Chapel Hill
Pulmonary Disease, Chronic Obstructive
A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at data from people with chronic obstructive pulmonary disease (COPD). Some used Stiolto Respimat and the others Trelegy Ellipta as their first treatment for COPD.
- Trial name
- NCT05169424
- Testing
- Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg)
- Where
- United States
- Volunteers
- 9,117 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD
Patients who are hospitalized at select Carolinas Healthcare System (CHS) sites with Chronic Obstructive Pulmonary Disorder (COPD) acute exacerbation symptoms will be treated per the CHS COPD Clinical Pathway.
- Trial name
- NCT03207776
- Testing
- Usual Care, COPD Clinical Pathway
- Where
- 8 sites in United States
- Volunteers
- 4,832 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Obstructive Pulmonary Disease
Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPD
Exacerbations of chronic obstructive pulmonary disease (COPD) are the first cause of admission to Pulmonary Department in Italy and worldwide.
- Trial name
- NCT01125098
- Testing
- PRO-CT values
- Where
- Italy
- Volunteers
- 183 people
- Sponsor
- University of Modena and Reggio Emilia
Chronic Obstructive Pulmonary Disease
Integrating Care After Exacerbation of COPD
This clinical trial is designed to determine whether an intervention that provides information to primary care providers about gaps in care for their patients recently discharged from hospital for COPD can reduce hospital…
- Trial name
- InCasE (NCT02021955)
- Testing
- guideline treatment recommendations
- Where
- 2 sites in United States
- Volunteers
- 717 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease With Exacerbation, Chronic Obstructive Pulmonary Disease Exacerbation
Bubble PEP Training Among Patient With Chronic Obstructive Pulmonary Disease in Pulmonary Function Effects
The morbidity rate of Chronic Obstructive Pulmonary Disease (COPD) is increasing year by year. It is predicted to be the third leading cause of death worldwide in 2030.
- Conditions
- Chronic Obstructive Pulmonary Disease With Exacerbation, Chronic Obstructive Pulmonary Disease Exacerbation, Chronic Pulmonary Disease
- Trial name
- NCT04828837
- Testing
- bubble PEP
- Where
- Taiwan
- Volunteers
- 57 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
COPD Exacerbation
Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy
Determination of specific molecular breath patterns by secondary electrospray ionization mass spectrometry (SESIHRMS) during and 8 weeks after a COPD exacerbation.
- Trial name
- TripleEX (NCT04638920)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 35 people
- Sponsor
- Malcolm Kohler
Respiratory Disorders
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
The purpose of this study is to test if the vaccine is working well in COPD patients aged 40 to 80 years old to reduce episodes of worsening symptoms ("exacerbations") and to gather further information on safety and immune…
- Trial name
- NCT03281876
- Testing
- NTHi Mcat investigational vaccine (GSK3277511A)
- Where
- 67 sites in United States, Belgium and 6 more
- Volunteers
- 606 people
- Sponsor
- GlaxoSmithKline
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies
- Trial name
- GALATHEA (NCT02138916)
- Testing
- Benralizumab Arm A, Benralizumab Arm B
- Where
- 407 sites in United States, Austria and 15 more
- Volunteers
- 1,656 people
- Sponsor
- AstraZeneca
COPD Exacerbation Acute
Treatment of Pneumocystis in COPD (the TOPIC Study)
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease associated with chronic inflammation in the airways and lung, resulting in significant morbidity and mortality worldwide.
- Trial name
- NCT05418777
- Testing
- Trimethoprim Sulfamethoxazole
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Corewell Health East
COPD, Eosinophilia
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.
- Trial name
- COPD-HELP (NCT04075331)
- Testing
- Mepolizumab
- Where
- United Kingdom
- Volunteers
- 238 people
- Sponsor
- University of Leicester
Chronic Obstructive Pulmonary Disease
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed…
- Trial name
- REACT (NCT01329029)
- Testing
- Roflumilast
- Where
- 180 sites in Australia, Austria and 19 more
- Volunteers
- 1,945 people
- Sponsor
- AstraZeneca
COPD
Evaluation the Effectiveness of a Telemonitoring Program in a Cohort of COPD Patient With Frequent Readmissions
Observational non-randomized study with an intervention cohort from Hospital Galdakao-Usansolo with 119 patients and a control cohort from Hospital Cruces with 78 patients.
- Trial name
- telEPOC (NCT02528370)
- Testing
- telEPOC
- Volunteers
- 197 people
- Sponsor
- Dr. Cristobal Esteban
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)
The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00297102
- Testing
- Roflumilast
- Where
- 179 sites in United States, Australia and 9 more
- Volunteers
- 1,523 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)
This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444)) delivered once daily via a Novel…
- Trial name
- NCT01551758
- Testing
- FF/VI, Existing Maintenance Therapy
- Where
- 178 sites in United Kingdom
- Volunteers
- 2,802 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- TREAT (NCT01473758)
- Testing
- Roflumilast
- Where
- 2 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
COPD Exacerbation
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized…
- Trial name
- NCT04655170
- Testing
- Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Tennessee Graduate School of Medicine
COPD Exacerbation
Increasing Adherence to Pulmonary Rehabilitation After COPD Related Hospitalizations (Pilot Study)
This pilot study will look at investigating barriers, facilitators, adherence and effectiveness of an interactive home-based pulmonary rehabilitation program and health coaching for patients who have recently been hospitalized…
- Trial name
- NCT03865329
- Testing
- Intervention- Home-based Pulmonary Rehabilitation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic